Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Randomized Multicenter Global Study Comparing Pulsed Field Ablation (PFA) Versus Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation

NCT06096337 is registered in ClinicalTrials.gov with Boston Scientific Corporation as lead sponsor.

NCT NCT06096337
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06096337 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Randomized Multicenter Global Study Comparing Pulsed Field Ablation (PFA) Versus Anti-Arrhythmic Drug (AAD) Therapy as a First Line Treatment for Persistent Atrial Fibrillation
Lead sponsor
Boston Scientific Corporation
Phase
Not applicable
Overall status
Active, not recruiting
Start date
December 28, 2023
Completion date
February 4, 2028
Enrollment
484 (actual)
Sites
61

Conditions

As the registry lists them; a condition with its own page is linked.

persistent atrial fibrillation